Subtype
Esophageal Squamous Cell Carcinoma
CI-CAN-00002629ESCCExplore in graph →
Loading cancer entity…
Subtype
CI-CAN-00002629ESCCExplore in graph →
Variants & evidence
17 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| AURKA EXPRESSION1 | |||||||
| Cisplatin + Fluorouracil + Radiation TherapyCombination | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1653A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated… (full text at CIViC) PMID 25924824 · Tamotsu et al., 2015 · Open in CIViC | civic |
| AXL EXPRESSION1 | |||||||
| (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID1655Immunohistochemical analysis of tumors from 116 esophageal squamous cell carcinoma found that expression of AXL was associated with increased progression of the tumor (P < 0.0001), increased risk of d… (full text at CIViC) PMID 27172793 · Hsieh et al., 2016 · Open in CIViC | civic |
| CDKN2A RS38149601 | |||||||
| (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1635124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray. The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.3… (full text at CIViC) PMID 27414035 · Li et al., 2016 · Open in CIViC | civic |
| EGFR L861Q1 | |||||||
| Afatinib | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID9679This retrospective preclinical study assessed the efficacy of afatinib towards esophageal squamous cell carcinoma (ESCC) cell lines expressing EGFR L861Q mutation. In one experiment, a ESCC KYSE270 EG… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| EGFR Overexpression4 | |||||||
| (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID78455 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 ± 0.5 … (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC | civic |
| Unspecified therapy | Predictive | B | Does Not Support Sensitivity Response | 3 | rejected | EID833Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS. PMID 26459251 · Jia et al., 2016 · Open in CIViC | civic |
| (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | rejected | EID834Overexpression of EGFR in 55 samples of esophageal squamous cell carcinoma as assesesed by IHC, was related to poor OS and PFS (PFS: 5.8 ± 0.5 vs. 11.0 ± 2.8 months, P = 0.007; OS: 9.7 ± 0.5 vs. 21.5… (full text at CIViC) | |
| EGFR Y69FS*111 | |||||||
| Erlotinib | Predictive | D | Supports Resistance | — | submitted | EID4808In an in vitro study, an esophageal squamous cell carcinoma cell line KYSE70 expressing EGFR Y69fs*11 mutation was associated with insensitivity to erlotinib treatment (IC50=4.31uM). Resistance was de… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| EP300 Y1414C1 | |||||||
| (oncogenic) | Oncogenic | D | Supports Oncogenicity | 2 | submitted | EID9573Mutations in histone modifier genes were analyzed in exome sequence data from 113 esophageal squamous cell carcinoma tumors. KYSE-150 and KYSE-450 ESCC cell lines were depleted of EP300 using shRNA, t… (full text at CIViC) PMID 25151357 · Gao et al., 2014 · Open in CIViC | civic |
| ERBB3 D297Y1 | |||||||
| Afatinib + Cetuximab + ErlotinibSubstitutes | Predictive | D | Does Not Support Sensitivity Response | 2 | submitted | EID9675In an in vitro study, an esophageal squamous cell carcinoma (ESCC) cell line KYSE150 expressing ERBB3 (HER3) D297Y mutation was associated with insensitivity to cetuximab, afatinib, and erlotinib trea… (full text at CIViC) PMID 27207775 · Nakamura et al., 2016 · Open in CIViC | civic |
| TACC3 Fusion1 | |||||||
| Unspecified therapy | Predictive | B | Does Not Support Sensitivity Response | 3 | rejected | EID2962In this report, Mizukami et al. explored major FGFR1, FGFR2, and FGFR3 fusion transcripts in ESCC and GC specimens (n = 74 and 114, respectively) using a most comprehensive next-generation sequencing … (full text at CIViC) PMID 27771611 · Mizukami et al., 2017 · Open in CIViC | civic |
| MDM2 RS348863281 | |||||||
| (prognostic) | Prognostic | B | Supports Better Outcome | 2 | accepted | EID1636124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray. Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival… (full text at CIViC) PMID 27414035 · Li et al., 2016 · Open in CIViC | civic |
| MYC Overexpression1 | |||||||
| Ganetespib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID10151Collectively data from expression analysis of 102 esophageal squamous cell carcinoma (ESCC) sample tissues established MYC and HSP90 as potential targets with overexpression of MYC observed in over ha… (full text at CIViC) PMID 32308431 · Guan et al., 2020 · Open in CIViC | civic |
| TP53 Mutation1 | |||||||
| (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID519In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival. PMID 19941080 · Yamasaki et al., 2010 · Open in CIViC | civic |
| TP53 V197E1 | |||||||
| (predisposing) | Predisposing | C | Supports Predisposition | 1 | submitted | EID9846Analysis of 77 esophageal squamous cell carcinoma tumor and normal samples for germline mutations revealed a rare TP53 V197E variant in a single patient. The V197E mutation is in the DNA-binding domai… (full text at CIViC) PMID 30833958 · Deng et al., 2019 · Open in CIViC | civic |
| WEE1 Overexpression1 | |||||||
| Adavosertib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID9232Within a preclinical study the inhibitory effects of AZD1775 in esophageal squamous cell carcinoma (ESCC) was demonstrated in both in vitro and in-vivo samples that predominantly displayed high expres… (full text at CIViC) PMID 31427973 · Bi et al., 2019 · Open in CIViC | civic |
Data updated 22 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
PMID 26459251 · Jia et al., 2016 · Open in CIViC
| civic |
| Nimotuzumab | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID78355 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to mod… (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC | civic |